Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2022-11-28 AGM Information
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
CEO Presentation to 2022 AGM 20 pages 2.1MB
AGM Information Classification · 95% confidence The document is a detailed presentation from Pharmaxis dated 29 November 2022, clearly labeled as '2022 AGM' and includes extensive information about the company's clinical programs, pipeline, financial position, and strategic updates. It contains forward-looking statements, program updates, clinical trial designs, and financial summaries typical of materials shared during an Annual General Meeting. There is no indication that this is a full annual report (10-K), earnings release, or regulatory filing. The presence of CEO remarks and comprehensive company overview aligns with AGM presentation materials. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and content depth support this classification with high confidence.
2022-11-28 English
Chairman's Address to Shareholders 3 pages 181.7KB
AGM Information Classification · 95% confidence The document is titled 'Pharmaxis Ltd Annual General Meeting 29 November 2022 Address by Chair, Malcolm J McComas' and contains a detailed speech given at the AGM. It discusses company strategy, clinical trial updates, management changes, and financial positioning, typical of AGM presentations. There is no indication that this is a full annual report or financial statements, nor is it a brief announcement or voting result. The content aligns with materials shared during an Annual General Meeting. The document length (8388 characters) supports it being a presentation or address rather than a short announcement or certification. Therefore, the document fits the category of AGM Information (AGM-R).
2022-11-28 English
Results of Meeting 2 pages 219.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal letter addressed to the Australian Securities Exchange regarding the outcome of resolutions passed at the Annual General Meeting (AGM) of Pharmaxis Ltd held on 29 November 2022. It includes detailed voting results for each resolution, consistent with the requirements of ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001. The content focuses exclusively on the results of shareholder votes at the AGM, with no financial statements or other report content. The document length is 4403 characters, which is relatively short and typical for a voting results announcement rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-28 English
Notification regarding unquoted securities - PXS 6 pages 28.1KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities, specifically performance rights issued under an employee incentive scheme. It details the number of securities issued, the date of issue, and mentions key management personnel involved. The document is an announcement of a securities issuance event rather than a full financial report or detailed analysis. It fits the category of announcements related to share issues or capital changes. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief report publication announcement or a regulatory filing fallback.
2022-11-28 English
Change of Director's Interest Notice 2 pages 143.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares and options acquired or disposed, dates of changes, and nature of the transactions. The document is a formal notification of insider share transactions by a director, which aligns with the definition of Director's Dealing filings. The document length is 3551 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, earnings release, or any other type of financial or regulatory report. Therefore, the correct classification is Director's Dealing (DIRS).
2022-11-28 English
Application for quotation of securities - PXS 6 pages 27.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities (employee incentive scheme options exercised). There is no financial performance data, earnings information, or management discussion. The document is an announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. This fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief notice but a detailed application for quotation of securities.
2022-11-22 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.